Dasatinib

目录号:S1021 别名: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。

规格 价格 库存 购买数量  
RMB 1142.64 现货
RMB 1224.97 现货
RMB 3039.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献66篇:

客户使用该产品的13个实验数据:

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。
靶点
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型(除了T315I)的Ba/F3增殖时,Dasatinib效果比Imatinib高很多。与Imatinib相比,Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型(除了T315I)。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域,且抑制自磷酸化和底物磷酸化,这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时,效果比Imatinib高325倍多。[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。 有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖,而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。[2] Dasatinib 处理一系列甲状腺癌细胞,抑制Src信号, 降低生长速度,使细胞周期停滞,且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天,抑制50%细胞生长,然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP,SW1736 和 K1 细胞,导致G1期细胞提高9-22%,而S期细胞百分数则降低7-18%。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 M4Sz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M334Z|czKGh? NYniOHFoTE2VTx?= M2jMbmlEPTB;MD6wNFAxPyEQvF2= MkOzNVc6PTZyOEC=
K562 NYfBSXlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILpSlc4OiCq Ml3HSG1UVw>? NVG5TJlGUUN3ME2wMlAxOSEQvF2= NVLwTIROOTd7NU[wPFA>
M07e Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S2TlczKGh? NUjtXZFbTE2VTx?= M3m5SmlEPTB;MD6wNFEzKM7:TR?= MWKxO|k2PjB6MB?=
ALL3 NVjZ[m12S3m2b4TvfIlkKEG|c3H5 M{nkeFAvOc7:TR?= MYS3NkBp MWLEUXNQ M4\TRWlEPTB;MD6wNFA1KM7:TR?= MUCxPVg5QTV2MB?=
CML MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXJR3IzOCCvaX6= NFi1Z5VFVVOR M3TNT2lEPTB;MD6wNFEh|ryP NHrTc4IyQTJzOUCxOi=>
BA/F3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XnbFczKGh? NX74OIR2TE2VTx?= M1rLVWlEPTB;Nj61PFkh|ryP MViyN|A5QDZ2NB?=
BA/F3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHBO|IhcA>? M3Xae2ROW09? M3jHRmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh|zszN MVWyN|A5QDZ2NB?=
BA/F3 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DUVFczKGh? MYDEUXNQ NHzhVmJKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP MWOyN|A5QDZ2NB?=
BA/F3 M3;hSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjpNW44OiCq M4jq[mROW09? NVW5dHhjUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN M2LBVFI{ODh6NkS0
BA/F3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zkS|czKGh? NXXnbmxTTE2VTx?= NGLabnBKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCINEi2V{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAxQc7:TR?= MVGyN|MxOTdyMx?=
BA/F3 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zrXVczKGh? NEnrO2VFVVOR M2rMeGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP MnTuNlM{ODF5MEO=
BA/F3 MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjWcow4OiCq NFq1VlJFVVOR M2jmcWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP M2rme|I{OzBzN{Cz
BA/F3 Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjmR204OiCq MnrRSG1UVw>? NEWwPG1KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCTMkWyTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA5|ryP MlHGNlM{ODF5MEO=
BA/F3 MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\M[lczKGh? M4jYUGROW09? MUnJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>? M4LoRlI{OzBzN{Cz
BA/F3 NVzOZXlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O0S|czKGh? MUTEUXNQ MYHJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> MUOyN|MxOTdyMx?=
BA/F3 M{D1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe3NkBp MX\EUXNQ MYrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? MmLvNlM{ODF5MEO=
BA/F3 MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHvcGg4OiCq NYfOdYN2TE2VTx?= NEXWSWFKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? NHLKUnozOzNyMUewNy=>
BA/F3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;aPFY4OiCq M3nGb2ROW09? NFvIeopKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2= NWmweXJxOjN|MEG3NFM>
T cell Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfVO|IhcA>? NYLEV5ZzTE2VTx?= MlL5TY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0> M4DUb|E4OTV2NUGy
WiDr NHTPPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXSfoN3PzJiaB?= MWXEUXNQ MoXxTWM2OD1yLkC1NkDPxE1? NXLFco1qOTV4MUW1NVI>
PC3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonGO|IhcA>? NUXIbYs5TE2VTx?= NX7CW2J1UUN3ME2wMlAxQTRizszN MWOxOVYyPTVzMh?=
MDA-MB-231 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXS3NkBp MlrLSG1UVw>? M3zlPGlEPTB;MD6wNVIh|ryP MV6xOVYyPTVzMh?=
Hs578T NIjhe4dEgXSxdH;4bYMhSXO|YYm= MYW3NkBp MlfWSG1UVw>? MnjPS2k2OD1yLkCzJO69VQ>? NXfzeIxCOjRyMUWzNlc>
HMEC M4TnXGN6fG:2b4jpZ{BCe3OjeR?= M3HMVFczKGh? NW\0c3djTE2VTx?= M1HiXGdKPTB;MT64JO69VQ>? NVn2[oh7OjRyMUWzNlc>
DU145 NV7rVnRbS3m2b4TvfIlkKEG|c3H5 NHHtV5Y4OiCq NUnvNmpnTE2VTx?= NGPZW2NIUTVyPUCuNVYh|ryP MXqyOFAyPTN{Nx?=
U251 NWDNV2V1S3m2b4TvfIlkKEG|c3H5 MVy3NkBp M2H5fWROW09? MkXzS2k2OD1{LkixJO69VQ>? MkfxNlQxOTV|Mke=
NCI60 MV;DfZRwfG:6aXOgRZN{[Xl? NEL0Ooc4OiCq MXjEUXNQ M{G0ZmdKPTB;NT63JO69VQ>? MUWyOFAyPTN{Nx?=
MALME-3M M17MXGN6fG:2b4jpZ{BCe3OjeR?= Moj2O|IhcA>? MVXEUXNQ NWThbFBwT0l3ME22MlYyKM7:TR?= NGXYfJczPDBzNUOyOy=>
KM12 M{PaWmN6fG:2b4jpZ{BCe3OjeR?= M3LsOlczKGh? M13tdWROW09? M2S4RmdKPTB;Nz60OEDPxE1? NIPUS2UzPDBzNUOyOy=>
SW620 NV;QeJA4S3m2b4TvfIlkKEG|c3H5 NFu3NWc4OiCq NYTZfG9qTE2VTx?= MmLpS2k2OD16LkSzJO69VQ>? NF3tN5czPDBzNUOyOy=>
RXF 393NL MoHGR5l1d3SxeHnjJGF{e2G7 Mo\rOEBl[Xm| M{LRUGROW09? MX7JR|UxRTBwMEKxO{DPxE1? M1;H[VI{OjV|MEe0
LXFA 983L NVewfpo{S3m2b4TvfIlkKEG|c3H5 NGq1e2I1KGSjeYO= NHzhOFZFVVOR NIfQOXFKSzVyPUCuNFU3PSEQvF2= NUe3[2c2OjN{NUOwO|Q>
PRXF DU145 NIfJU4REgXSxdH;4bYMhSXO|YYm= NYXTb4lxPCCmYYnz MXvEUXNQ MUjJR|UxRTBwME[yN{DPxE1? NFjxZXMzOzJ3M{C3OC=>
PAXF 1657L NXy5RoRGS3m2b4TvfIlkKEG|c3H5 MUm0JIRigXN? Ml:5SG1UVw>? M1PGb2lEPTB;MD6xNlEh|ryP NYPTOHM{OjN{NUOwO|Q>
CXF 1103L NYq2fnpjS3m2b4TvfIlkKEG|c3H5 M3XNRVQh\GG7cx?= M4DxfGROW09? M1PNPWlEPTB;ND6zOkDPxE1? NH3BOXUzOzJ3M{C3OC=>
GXF251L MkfKR5l1d3SxeHnjJGF{e2G7 NETROWQ1KGSjeYO= MnWwSG1UVw>? NInzeZBKSzVyPUKuNlUh|ryP Ml;VNlMzPTNyN{S=
NCI-H23 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;i[4JsPzJiaB?= NIjDR2dFVVOR NGjuT|VKSzVyPUKuNlch|ryP MkXzNlM2OjFyMkC=
HCT116 M1XR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7YO|IhcA>? NV\OVJhqTE2VTx?= MkfhTWM2OD1{LkOg{txO Mn:zNlM2OjFyMkC=
MCF7 NFm2b|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXS3NkBp NFH2fo9FVVOR NUO5UpNsUUN3ME2yMlU4KM7:TR?= M3O1XFI{PTJzMEKw
NCI-H460 NEHCU2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7kO|IhcA>? NVLISolrTE2VTx?= NXzi[FNzUUN3ME24Mlk6KM7:TR?= M4fNW|I{PTJzMEKw
DLD1 Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:3NkBp NVf5TmZtTE2VTx?= NETSXpRKSzVyPUSuOkDPxE1? NUPsdoVvOjN3Nke5OlA>
NCI-H661 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfSO|IhcA>? M2DM[mROW09? NYX1OpV[UUN3ME23Mlgh|ryP NWDVbGtuOjN3Nke5OlA>
A549 NVftOllOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLINZU4OiCq M{HPfGROW09? M4i1dGlEPTB;OD6yJO69VQ>? M4O3[|I{PTZ5OU[w
U937 NVXKVVRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvjO|IhcA>? NF;rfI1FVVOR MnSyTWM2OD1zMj6yJO69VQ>? MljiNlM2Pjd7NkC=
HEK293 MoP1SpVv[3Srb36gRZN{[Xl? NGP3R4gyOMLizszN NFHYZ25FVVOR MkO2TY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2= NY\YXYVGOjJ5N{C2NVA>
HUVEC NVzDVlB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmwMlE2yqEQvF2= NIC5dpM4OiCq MWrEUXNQ MneyTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDheEAxNjF3IIXN NFzUU5AzOjh3M{m5Ny=>
HUVEC Ml\YSpVv[3Srb36gRZN{[Xl? MlzpNVXDqM7:TR?= MnjxO|IhcA>? M2\XVGROW09? NWTEPZVuUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? MUiyNlg2Ozl7Mx?=
Plasmodium falciparum MXvGeY5kfGmxbjDBd5NigQ>? NF;idlEyOMLizszN NXX1UI53OTVibXnu MknaSG1UVw>? Mo\yTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO Ml\zNlQ2PTB|M{C=
PC3 MVPGeY5kfGmxbjDBd5NigQ>? NGPVTIExNjFizszN M4PENVUhcA>? Mmj5SG1UVw>? Mn\VTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P M3vj[lE6PDZ{OUe1
DU145 MkHMSpVv[3Srb36gRZN{[Xl? NYTJbohJOC5zIN88US=> M2XwOVUhcA>? NGP0XY9FVVOR MknpTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= NYT4NJpCOTl2NkK5O|U>
PC3 MoW1T4lv[XOnIFHzd4F6 NIPyPXMxNjFizszN MlrFOUBp NUnKTVFCTE2VTx?= MkPVTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= NXG2Wo1OOTl2NkK5O|U>
DU145 NUiyRllYU2mwYYPlJGF{e2G7 MUWwMlEh|ryP NFnmTGo2KGh? M4L0c2ROW09? M33ycGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> M134OlE6PDZ{OUe1
PC3 M4Tid2tqdmG|ZTDBd5NigQ>? NGDBSGUxNjFizszN NHz6OFQ2KGh? NGXvRVlFVVOR MmPzTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O NEj6ZW0yQTR4Mkm3OS=>
DU145 M2HPOmtqdmG|ZTDBd5NigQ>? M1HNT|AvOSEQvF2= M4rzZlUhcA>? MnvNSG1UVw>? Ml;lTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? NFfXNmYyQTR4Mkm3OS=>
Huh7 NYns[5hrSW62aY\pdoFtKEG|c3H5 M3vYOVIvPSEQvF2= NVP6bHdZPCCmYYnz NWfZVWFMTE2VTx?= NVTLOWtvUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN NV3mXVRvOTd|NkC2O|Y>
C6/36 Mo\HRY51cX[rcnHsJGF{e2G7 MWqyMlUh|ryP MX:0JIRigXN? M1TNb2ROW09? MVLJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO MVqxO|M3ODZ5Nh?=
U937 M123OWZ2dmO2aX;uJGF{e2G7 MYexJO69VQ>? MlT1NUBp NWrUbFJRTE2VTx?= MXvS[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? NV[xUo5pOTd4OESwPVk>
U937 M{\yO2Z2dmO2aX;uJGF{e2G7 MlzoNUDPxE1? MnrpNUBp M3q4eGROW09? NGTDO5BT\WS3Y3XzJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? NHq0e4gyPzZ6NEC5PS=>
murine mast cell MkHrSpVv[3Srb36gRZN{[Xl? Mki3NUDPxE1? NXH4dIQ3OjRiaB?= NFSzR2JFVVOR M3;5O2lvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP MlzKNVc3QDRyOUm=
BV-173 NGrIcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMECwNFAxOTB7IN88US=> NGHCeJVUSU6JRWK=
K-562 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMECwNFAxOjZ4IN88US=> M3TrbXNCVkeHUh?=
BL-70 M{Drcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj0PIxKSzVyPUCuNFAxODByOEKyJO69VQ>? MVfTRW5ITVJ?
EM-2 M1y1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMECwNFAyODhizszN MVPTRW5ITVJ?
LAMA-84 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMECwNFA{OjFizszN M16xSXNCVkeHUh?=
MEG-01 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXZbo9[UUN3ME2wMlAxODByOUig{txO NEf4[G9USU6JRWK=
EoL-1-cell NIDtTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLUTWM2OD1yLkCwNFAyOzFizszN NGXXbpZUSU6JRWK=
CTV-1 M1PVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHvS21pUUN3ME2wMlAxODB2MESg{txO M2XCfXNCVkeHUh?=
TE-15 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEC1PFkh|ryP M2fPS3NCVkeHUh?=
NOS-1 MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\XVIViUUN3ME2wMlAxPjF|IN88US=> NX[wPFB5W0GQR1XS
D-336MG NHHT[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jnNWlEPTB;MD6wNFY{KM7:TR?= M1;BT3NCVkeHUh?=
LB1047-RCC NFjrNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXxTWM2OD1yLkCwPVg6KM7:TR?= M4HPN3NCVkeHUh?=
LB996-RCC M3LNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnuO5p[UUN3ME2wMlAxQTlzIN88US=> NF3FUZVUSU6JRWK=
SW982 MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\P[pZKSzVyPUCuNFEyOTVizszN NEjTeWtUSU6JRWK=
TK10 NHuzXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMEGxO|Qh|ryP NUPZ[|ltW0GQR1XS
A704 NILzOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLwTWM2OD1yLkCxOFkyKM7:TR?= NFPTeHZUSU6JRWK=
TE-8 NVLKdpFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HmOmlEPTB;MD6wNVU4PiEQvF2= MkXpV2FPT0WU
DOHH-2 MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMEG3NVkh|ryP M2PmWHNCVkeHUh?=
HOP-62 NHTXUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WyOGlEPTB;MD6wNVg{PCEQvF2= M{j1TXNCVkeHUh?=
TE-12 NIqzVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnxZ4NKSzVyPUCuNFE5PjFizszN NH7xXmtUSU6JRWK=
KGN MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzxT3pQUUN3ME2wMlAyQTR{IN88US=> NXH3Z2UzW0GQR1XS
NCI-H1648 NVzR[5FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF72No5KSzVyPUCuNFIxOTFizszN Mlm0V2FPT0WU
OS-RC-2 NFXqTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEKwN{DPxE1? MX;TRW5ITVJ?
GB-1 MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEKxOVch|ryP NX;RemY4W0GQR1XS
RXF393 M2nITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS1Vm1iUUN3ME2wMlAzOzV5IN88US=> NF7zemRUSU6JRWK=
LC-2-ad MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEK1PFYh|ryP NYTXSmQ4W0GQR1XS
KS-1 NVmyUnV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PIOWlEPTB;MD6wNlc{KM7:TR?= MX\TRW5ITVJ?
ETK-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHtUWpKSzVyPUCuNFI5OzJizszN MWDTRW5ITVJ?
SW954 M3ixVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml21TWM2OD1yLkCyPVI4KM7:TR?= MmnoV2FPT0WU
Becker MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13TUGlEPTB;MD6wN|AxOyEQvF2= NVLYendnW0GQR1XS
MZ1-PC M3;lbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzP[oxKSzVyPUCuNFMyOTlizszN NULHUGt2W0GQR1XS
ES6 NVXoR3hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITJTIdKSzVyPUCuNFMyQTNizszN Mle3V2FPT0WU
KURAMOCHI NHLXT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMEO0PFch|ryP M4LGcHNCVkeHUh?=
CGTH-W-1 M3nMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz4TWM2OD1yLkCzOVQ5KM7:TR?= M1HrWHNCVkeHUh?=
VA-ES-BJ M17tbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrETWM2OD1yLkCzPVAzKM7:TR?= M4XzPXNCVkeHUh?=
LXF-289 NITZZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMEO5OVYh|ryP MkDtV2FPT0WU
MPP-89 NHXTPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMESwOFkh|ryP M3nLRnNCVkeHUh?=
SW872 Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMESxOlEh|ryP M2L3SHNCVkeHUh?=
SNB75 M2XWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMES0N|Uh|ryP MUPTRW5ITVJ?
PSN1 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j3O2lEPTB;MD6wOFQ4PCEQvF2= MoHBV2FPT0WU
LB831-BLC NHvkS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOwVWlLUUN3ME2wMlA1PjB7IN88US=> NIHzWmdUSU6JRWK=
MFH-ino MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMES3NlQh|ryP MoWwV2FPT0WU
TGBC24TKB M2nOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfiTWM2OD1yLkC0O|YyKM7:TR?= MXzTRW5ITVJ?
A388 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljFTWM2OD1yLkC1NFk2KM7:TR?= MYrTRW5ITVJ?
BB30-HNC MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnHeWJKSzVyPUCuNFU1OzdizszN MUTTRW5ITVJ?
GI-ME-N MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mne0TWM2OD1yLkC2NVE5KM7:TR?= NH7xO3RUSU6JRWK=
TGBC1TKB NIn6dVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\oTI9KSzVyPUCuNFYyPjRizszN M3PtXXNCVkeHUh?=
TE-10 NGfTNZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP6[3dKUUN3ME2wMlA3OzV5IN88US=> MVHTRW5ITVJ?
A498 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvKU5ZJUUN3ME2wMlA4Ojh2IN88US=> MorFV2FPT0WU
TE-11 NICzO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfqTWM2OD1yLkC3PFU5KM7:TR?= NWTxepJUW0GQR1XS
BB65-RCC NUXLc25[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nOOmlEPTB;MD6wPFIzPyEQvF2= NV7Vd2wzW0GQR1XS
C2BBe1 NXv5UJR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3eyTmlEPTB;MD6wPFMxQCEQvF2= M17wSXNCVkeHUh?=
NCI-H747 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEizOlIh|ryP MnfYV2FPT0WU
IST-MES1 NUnlSocxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f3V2lEPTB;MD6wPFU2OiEQvF2= MnjHV2FPT0WU
KALS-1 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoeyTWM2OD1yLkC5OFkh|ryP MVTTRW5ITVJ?
GCIY MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj1TWM2OD1yLkC5OlU3KM7:TR?= M3T6UXNCVkeHUh?=
RL95-2 NWL3XphUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMUCzPEDPxE1? M1S2SXNCVkeHUh?=
TE-1 M4\rNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPiblFCUUN3ME2wMlExPTRizszN MlvWV2FPT0WU
NCI-H1355 NU\2NlNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLDemE5UUN3ME2wMlEyODJ6IN88US=> MnizV2FPT0WU
SW962 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\xdIxKSzVyPUCuNVEzQTJizszN MUXTRW5ITVJ?
KLE NWP1UlJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMUGzNVch|ryP MlXCV2FPT0WU
MC116 NET6e4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H1fGlEPTB;MD6xNVQyKM7:TR?= M2m3PXNCVkeHUh?=
NMC-G1 NY\Db3UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXWW4NKSzVyPUCuNVE3ODZizszN MkjvV2FPT0WU
KU812 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3G1SmlEPTB;MD6xNVg5OyEQvF2= Mme1V2FPT0WU
COLO-829 NX3ONIFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXpblJKSzVyPUCuNVIzOTNizszN M1TkU3NCVkeHUh?=
NTERA-S-cl-D1 Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvSTWM2OD1yLkGyNlg{KM7:TR?= NGHr[nRUSU6JRWK=
IST-MEL1 NXnIZZNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfVRXdKSzVyPUCuNVM1PSEQvF2= NXu1bJRTW0GQR1XS
MLMA MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoniTWM2OD1yLkG0NFMzKM7:TR?= M{TRN3NCVkeHUh?=
LS-123 MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVmyR|NWUUN3ME2wMlE1ODZ2IN88US=> MoHmV2FPT0WU
LB2518-MEL NYHxXm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TMUGlEPTB;MD6xOFE3OiEQvF2= MnrZV2FPT0WU
NB69 MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMUS0N|Yh|ryP MlG4V2FPT0WU
8-MG-BA NHvJZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf6TJVKUUN3ME2wMlE2PDV6IN88US=> M4HNU3NCVkeHUh?=
K5 MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMU[0PFkh|ryP MoT3V2FPT0WU
KINGS-1 NGezc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O4ZWlEPTB;MD6xOlY3PiEQvF2= NIjHVGlUSU6JRWK=
SF268 NYTFNGVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLMTWM2OD1yLkG3OFA1KM7:TR?= M1rUVHNCVkeHUh?=
PF-382 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX1[ZYzUUN3ME2wMlE4Pjd6IN88US=> MULTRW5ITVJ?
SH-4 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL3[o97UUN3ME2wMlE5PDF|IN88US=> NX\kU41tW0GQR1XS
NALM-6 NIruR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jWdWlEPTB;MD6xPVI6PSEQvF2= MWjTRW5ITVJ?
CP66-MEL MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMUm1N|Eh|ryP MmjsV2FPT0WU
697 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzadFVKSzVyPUCuNVk6QDdizszN M1TUOHNCVkeHUh?=
CP67-MEL NVu0PWtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjXUYllUUN3ME2wMlIxPDh6IN88US=> NXXYNFJpW0GQR1XS
DSH1 M2rHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PBV2lEPTB;MD6yOFAxOSEQvF2= NHPzO3pUSU6JRWK=
HCE-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFyzfVVKSzVyPUCuNlY1OzlizszN M{Hqd3NCVkeHUh?=
MZ2-MEL MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlW4TWM2OD1yLkK4OVM4KM7:TR?= M1fTSXNCVkeHUh?=
BL-41 NE[1blRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\acpNKSzVyPUCuNlkyOjNizszN NH;HV4FUSU6JRWK=
HUTU-80 NVLrfIt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwM{G0NkDPxE1? NXzuRm1iW0GQR1XS
LOXIMVI NHj6[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnTcFNHUUN3ME2wMlMyPTB|IN88US=> NFLYV4tUSU6JRWK=
no-10 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwM{G5N|Eh|ryP Ml;EV2FPT0WU
KARPAS-422 NWTvbJd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTQTWM2OD1yLkOzPVk4KM7:TR?= M{XJVXNCVkeHUh?=
SW684 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HMOmlEPTB;MD6zOFk5KM7:TR?= NFjZ[I9USU6JRWK=
SF126 NFjQc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TtXmlEPTB;MD6zOVQyKM7:TR?= MkLPV2FPT0WU
D-263MG NX;sNodYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwM{[yNlQh|ryP NImxU2hUSU6JRWK=
OVCAR-4 M{ex[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS3TWM2OD1yLkO3OFM{KM7:TR?= MWnTRW5ITVJ?
BB49-HNC MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jD[WlEPTB;MD6zPFU6QSEQvF2= M4T3dnNCVkeHUh?=
ONS-76 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwNEK5OVEh|ryP NGXrUXJUSU6JRWK=
MZ7-mel NG\5VYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HYemlEPTB;MD60O|kyOSEQvF2= MX7TRW5ITVJ?
RCC10RGB MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\rUWlEPTB;MD60PVEyKM7:TR?= NH7jOZpUSU6JRWK=
BOKU M1XGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rURmlEPTB;MD60PVE{OyEQvF2= MU\TRW5ITVJ?
no-11 M{XsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jGV2lEPTB;MD61NFIzQCEQvF2= MnfiV2FPT0WU
IST-SL2 MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwNUCzNFIh|ryP NEPsOGFUSU6JRWK=
RKO NUj1b5V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfwTWM2OD1yLkWyPVY3KM7:TR?= MmnmV2FPT0WU
HT-144 NGnxenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH5TWM2OD1yLkWzOlA6KM7:TR?= MY\TRW5ITVJ?
NCI-H446 NWjQXWZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwNkK3OkDPxE1? MlLQV2FPT0WU
QIMR-WIL NHflV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrHeXl{UUN3ME2wMlcxPjJ7IN88US=> MlfxV2FPT0WU
MHH-PREB-1 NUS0eZhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwN{S0Olkh|ryP M1;4e3NCVkeHUh?=
EW-16 Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwN{[xO|gh|ryP M1S4[HNCVkeHUh?=
EW-24 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rETWlEPTB;MD63PFE3PSEQvF2= MkP6V2FPT0WU
LB373-MEL-D M3zTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP4NlhxUUN3ME2wMlgzPTB6IN88US=> NIHXeHBUSU6JRWK=
TE-9 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjmTWM2OD1yLki3OVMzKM7:TR?= NEfaU41USU6JRWK=
A3-KAW M{C3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH4T5pKSzVyPUCuPVg1PTJizszN NUTlflA4W0GQR1XS
A101D NHPEO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFwMEOwOFMh|ryP NYnkcYZLW0GQR1XS
OCUB-M NFfQPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwMES0NVIh|ryP NVTOd2hZW0GQR1XS
ES4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTx[I02UUN3ME2xMlA2OTR3IN88US=> NX7nZXduW0GQR1XS
TE-6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\SVXVWUUN3ME2xMlIyOjJ4IN88US=> NWDUZoljW0GQR1XS
D-502MG M1\1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jqcGlEPTB;MT6yN|M4PiEQvF2= MXrTRW5ITVJ?
KNS-42 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M160dWlEPTB;MT6yOFQyOiEQvF2= M1nmdHNCVkeHUh?=
SNU-C2B NGDXTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrtVGpKSzVyPUGuN|A2QDlizszN NUO4[GZQW0GQR1XS
NCI-H1838 NFzCc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HrfmlEPTB;MT6zNFc{OyEQvF2= NEHUSoVUSU6JRWK=
NKM-1 NV7aWJdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TOS2lEPTB;MT6zNFg2QSEQvF2= M1[yeHNCVkeHUh?=
GI-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzrNFJKSzVyPUGuN|YzOiEQvF2= NX23TWdrW0GQR1XS
NB5 Mn;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTITWM2OD1zLkO5PFI4KM7:TR?= MWLTRW5ITVJ?
CAS-1 NUCy[IE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwNEC5PVIh|ryP NYLSSXJrW0GQR1XS
HCE-T NYXqN5lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTFwNU[3NVQh|ryP M1z5dHNCVkeHUh?=
SBC-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLIT5JLUUN3ME2xMlU4QTh2IN88US=> NUi3SINzW0GQR1XS
JiyoyeP-2003 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLtTG1IUUN3ME2xMlc{PDZ4IN88US=> MVXTRW5ITVJ?
TE-5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDXc|RQUUN3ME2xMlc6OTN7IN88US=> Mn[yV2FPT0WU
CAN NYLpcWhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFwOEKyOVIh|ryP M{nWbXNCVkeHUh?=
SK-UT-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qzbGlEPTB;Mj6xOlY6OyEQvF2= NUXBPGJyW0GQR1XS
JVM-2 M4PpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DYdGlEPTB;Mj6zOlI5PCEQvF2= NUD0[mFYW0GQR1XS
LB771-HNC NGq2T|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPFdJdKSzVyPUKuOVc2PTFizszN MmLLV2FPT0WU
NCCIT MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJwOE[2NVYh|ryP Mn[2V2FPT0WU
NCI-H2126 NYPp[nJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2naSWlEPTB;Mj64O|U2OiEQvF2= NIHFWm9USU6JRWK=
Calu-6 NHvHZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTNwMEW3OFEh|ryP NGjjR2xUSU6JRWK=
SK-LMS-1 NVjuWGdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M370eWlEPTB;Mz6xNVg5PiEQvF2= NGTSfJVUSU6JRWK=
ARH-77 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvRb41KSzVyPUOuOFY6OTVizszN M2O1XXNCVkeHUh?=
NB17 M{nmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;3fZpKSzVyPUOuOlM5PDdizszN NHjZO2FUSU6JRWK=
A253 M4HIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNwN{OyOFYh|ryP MXLTRW5ITVJ?
OPM-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3wTWM2OD12LkK3Olg2KM7:TR?= MVXTRW5ITVJ?
MV-4-11 NFzK[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwM{[0OVQh|ryP NIf2b4VUSU6JRWK=
SR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e1cGlEPTB;ND60PVk2PCEQvF2= NEDlU2tUSU6JRWK=
KG-1 NF[0O5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fFd2lEPTB;ND62NFg1PSEQvF2= MoW5V2FPT0WU
OCI-AML2 M3\QfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD5TWM2OD13Lki2NVU1KM7:TR?= NXT6eJczW0GQR1XS
D-247MG Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTZwMUK1NVkh|ryP MlnYV2FPT0WU
DJM-1 M1W2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLOXoFCUUN3ME22MlQ5PTV6IN88US=> M331TXNCVkeHUh?=
RPMI-6666 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTdwMkewOlch|ryP NHTPOlBUSU6JRWK=
KARPAS-45 M4nVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv2WlRKSzVyPUeuOVE3PzFizszN M2rBb3NCVkeHUh?=
LP-1 NXrDcnVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTr[VNKSzVyPUeuOVQ4QDJizszN M{nTdnNCVkeHUh?=
RS4-11 M2q4eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm0PY5KSzVyPUeuOlU4QDdizszN MVjTRW5ITVJ?
DU-4475 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHPTWM2OD16LkKxOlUzKM7:TR?= NW\LZ3VxW0GQR1XS
MONO-MAC-6 M3GydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRThwMkewOlYh|ryP MX7TRW5ITVJ?
NCI-SNU-16 NEXlXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRThwNU[xNlgh|ryP M{jj[XNCVkeHUh?=
SJSA-1 NX;FdItvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRThwN{K4NFUh|ryP NHmxclNUSU6JRWK=
MMAC-SF M1nhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLnXG9KSzVyPUiuO|k{ODdizszN M3jYZnNCVkeHUh?=
SK-NEP-1 NWnYdWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDBOmI1UUN3ME24Mlg6OTV3IN88US=> Mmj3V2FPT0WU
J-RT3-T3-5 M1LSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRThwOU[1Nlkh|ryP NGDqWI1USU6JRWK=
SKM-1 M4jpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fQVmlEPTB;OT6wNVc{PCEQvF2= MlXkV2FPT0WU
LB2241-RCC NG\MfnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTlwMEKwNVIh|ryP NYXxWW01W0GQR1XS
SIG-M5 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3sTWM2OD17LkCyOFk{KM7:TR?= MnPmV2FPT0WU
EVSA-T NIPk[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jSOGlEPTB;OT6yO|c6OyEQvF2= M4OxSXNCVkeHUh?=
GT3TKB NEDNXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{SySWlEPTB;OT6zOVU1PiEQvF2= MUjTRW5ITVJ?
NB6 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTMWJV2UUN3ME25MlkzOjV7IN88US=> NHXVfnRUSU6JRWK=
EHEB NYfWRWpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X5cmlEPTB;MUCuNFY2PiEQvF2= NFrBXYNUSU6JRWK=
HEL M3T0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\hWGlEPTB;MUCuOFc4PiEQvF2= NUThUlBTW0GQR1XS
ALL-PO NVPxT4dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G0VmlEPTB;MUCuO|k{QCEQvF2= NXnvUFdiW0GQR1XS
TGW MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HjSGlEPTB;MUGuNlgzQCEQvF2= M1rFN3NCVkeHUh?=
BC-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDNTWM2OD1zMj6xNVM5KM7:TR?= MlOyV2FPT0WU
IA-LM MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTCTWM2OD1zMj60OFQ2KM7:TR?= MonRV2FPT0WU
UACC-257 Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF{LkmxPVgh|ryP M3fa[nNCVkeHUh?=
KP-N-YS NW\vUHNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF{LkmyPFMh|ryP NHLDfYxUSU6JRWK=
Raji Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHlVHhKSzVyPUGzMlc1QTdizszN NWjYSoF2W0GQR1XS
SF539 M{fyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u0eWlEPTB;MUOuPFU2PyEQvF2= NUCxbHhmW0GQR1XS
DMS-153 NVrINmJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF2LkCwNlgh|ryP NHPIPJFUSU6JRWK=
L-540 NWexO3NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLnTWM2OD1zNT6wOlczKM7:TR?= NXvTepVxW0GQR1XS
MN-60 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W4O2lEPTB;MUWuNVk4QSEQvF2= MlvmV2FPT0WU
RPMI-8866 NWnxTJpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITYVmRKSzVyPUG3MlQ1PTRizszN M{\QXXNCVkeHUh?=
NCI-H510A MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF7LkO5O|Mh|ryP NXHaWnpwW0GQR1XS
NB13 M2\uU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HkNmlEPTB;MUmuOFg4PyEQvF2= NIHKbZhUSU6JRWK=
HAL-01 M1TyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvrOoFMUUN3ME2xPU44PTR|IN88US=> NHjQPWtUSU6JRWK=
NCI-H720 MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLsfWNEUUN3ME2yNE4zPzN|IN88US=> M1HVVnNCVkeHUh?=
REH NIfpWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7jZ2ZKSzVyPUKwMlY{PTdizszN NHTR[pdUSU6JRWK=
KNS-81-FD M3vsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DubGlEPTB;MkOuNVQ3KM7:TR?= MV\TRW5ITVJ?
HC-1 M2PEO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;TTWM2OD1{ND61OVUyKM7:TR?= M3TWfXNCVkeHUh?=
NCI-H2141 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3FNmVtUUN3ME2yOE44PzV2IN88US=> NYDoeFFLW0GQR1XS
MOLT-4 M2XWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ywVWlEPTB;Mk[uOlc2OyEQvF2= M3KzTXNCVkeHUh?=
OMC-1 NGnCeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJ5LkG0NlIh|ryP Mlf4V2FPT0WU
LC-1F Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ5LkOyOFUh|ryP NUTuVVlkW0GQR1XS
NCI-H1304 NY\2bFdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjMOHhKSzVyPUK4MlE3OjhizszN M2js[nNCVkeHUh?=
BC-1 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ6Lk[1NUDPxE1? M1r4V3NCVkeHUh?=
NCI-H64 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjvd4dRUUN3ME2yPU43OjV|IN88US=> M3zTPHNCVkeHUh?=
MOLT-16 NIfRdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW2TWM2OD1{OT62NlkzKM7:TR?= MoPFV2FPT0WU
U-87-MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXsUppKSzVyPUOwMlc3PiEQvF2= NGjET4FUSU6JRWK=
GAK NWDQTYNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonRTWM2OD1|MT6yOlg3KM7:TR?= MUjTRW5ITVJ?
ES8 M17nVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\3eWlEPTB;M{KuNVI2OiEQvF2= MVLTRW5ITVJ?
HCC1599 MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j0ZmlEPTB;M{KuN|MzPSEQvF2= MlzYV2FPT0WU
EB-3 NGrZXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPITWM2OD1|ND6zNVE4KM7:TR?= NEfTUWNUSU6JRWK=
HCC1187 NWCycm1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPPfHd3UUN3ME2zOU45ODV{IN88US=> NEj1XmlUSU6JRWK=
SK-PN-DW MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXOclVKSzVyPUO2MlE6PDNizszN MlH0V2FPT0WU
JVM-3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjBTVZKSzVyPUO3MlI{OzhizszN Moq1V2FPT0WU
HCC2157 NXfub2oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrvXoxKSzVyPUO3Mlk6PDZizszN NGXnZZdUSU6JRWK=
A4-Fuk NXXMNW45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTN6LkGwNFkh|ryP MV7TRW5ITVJ?
COR-L279 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTRyLkK4OVEh|ryP M{LW[XNCVkeHUh?=
DEL MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG4TWM2OD12MT65NFg3KM7:TR?= NWDIV5c2W0GQR1XS
NCI-H1395 NVPjfWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL2TWM2OD12Mj6wNVY{KM7:TR?= MU\TRW5ITVJ?
MHH-NB-11 M1\pRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG0Om9KSzVyPUSzMlA5OThizszN NWfPe403W0GQR1XS
NCI-H2107 NVTKbXRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnjTWM2OD12Mz60PFQ3KM7:TR?= Ml3pV2FPT0WU
NEC8 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\3TWM2OD12ND6zN|Yh|ryP NHHRfXdUSU6JRWK=
COLO-684 NFXkOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjvfmFNUUN3ME20Ok4zOjV6IN88US=> NFfNSFBUSU6JRWK=
LS-411N MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfFe25OUUN3ME20PE41PzR6IN88US=> MUfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 Dasatinib 作用于LMP2A/MYC 双转基因小鼠,可逆转脾肿大。Dasatinib 作用于TgE小鼠 抑制表达LMP2A 的骨髓B 细胞形成的菌落,且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠,与对照组相比,脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠,抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠,可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤,抑制Lyn磷酸化。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶自磷酸化分析:

使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白,ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30oC下温育1小时后,加入1 mM 钒酸钠,激活LAR磷酸酶。进行免疫印迹分析,比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶,使用磷酸化的特点抗体4G10来 确认酪氨酸残基完全去磷酸化(>95%),使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验: [1]
+ 展开
  • Cell lines: Ba/F3细胞系
  • Concentrations: 0 nM-32 nM
  • Incubation Time: 72小时
  • Method: Ba/F3 细胞系重复培养三份,然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 488.01
化学式

C22H26ClN7O2S

CAS号 302962-49-8
稳定性 powder
in solvent
别名 BMS-354825

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03041701 Recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2
NCT02011945 Active not recruiting Chronic Myeloid Leukemia Bristol-Myers Squibb February 7 2014 Phase 1
NCT02389309 Recruiting Solid Tumors M.D. Anderson Cancer Center October 5 2015 Phase 1
NCT02744768 Recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto May 31 2017 Phase 2
NCT01999985 Active not recruiting Lung Cancer|Non-small Cell Lung Cancer (NSCLC) H. Lee Moffitt Cancer Center and Research Institute|Boehringer Ingelheim|Bristol-Myers Squibb December 31 2013 Phase 1
NCT01660971 Active not recruiting Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7 National Cancer Institute (NCI) July 30 2012 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 问题 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品

Tags: 购买Dasatinib | Dasatinib供应商 | 采购Dasatinib | Dasatinib价格 | Dasatinib生产 | 订购Dasatinib | Dasatinib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID